Search Medical Condition
Please enter condition
Please choose location from dropdown

HUS, Finland Clinical Trials

A listing of HUS, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (214) clinical trials

Safety Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.

Phase

6.93 miles

Learn More »

Natural History of the Progression of Choroideremia Study

Choroideremia (CHM) is a rare, X-linked recessive, degenerative disease of the retina which begins in childhood with loss of night vision and gradually progresses to legal blindness by the fifth decade. There are no approved treatements for CHM and the disease is poorly characterised given its rare nature and scarscity ...

Phase N/A

6.93 miles

Learn More »

Brief Intervention for ICU Patients With Alcohol Use Disorders

Patients non-electively admitted to intensive care units (ICUs) will be screened for eligibility. The investigators will include adult patients with risk level alcohol use, defined by AUDIT-C score (>5 for females, >6 for males). Informed consent will be obtained from the patient in the end or shortly after the ICU ...

Phase N/A

6.93 miles

Learn More »

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

Phase

6.93 miles

Learn More »

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF. The secondary objectives are to investigate the effect of BI 1015550 on the target engagement biomarker and to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.

Phase

6.93 miles

Learn More »

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Phase

6.93 miles

Learn More »

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.

Phase

6.93 miles

Learn More »

Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia

This is a phase 3 clinical trial of a gene therapy vector made from adeno-associated virus (AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be required to attend a screening visit during which their suitability for the study will be assessed, and eligible subjects will be randomized ...

Phase

6.93 miles

Learn More »

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia.

The purpose of this study is to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation

Phase

6.93 miles

Learn More »

The Effects of Low Carbohydrate Diet on Liver Fat Content and Mitochondrial Fluxes

In this study, the investigators will examine whether a low carbohydrate diet will change hepatic lipid content and mitochondrial flux in humans. Before and after a low carbohydrate diet intervention, rates of hepatic mitochondrial flux will be assessed using positional isotopomer analysis of 3-13C-lactate during a 3 hour basal period. ...

Phase N/A

6.93 miles

Learn More »